[go: up one dir, main page]

AR101558A1 - Difluoropirrolidinas como moduladores del receptor de orexina - Google Patents

Difluoropirrolidinas como moduladores del receptor de orexina

Info

Publication number
AR101558A1
AR101558A1 ARP150102622A ARP150102622A AR101558A1 AR 101558 A1 AR101558 A1 AR 101558A1 AR P150102622 A ARP150102622 A AR P150102622A AR P150102622 A ARP150102622 A AR P150102622A AR 101558 A1 AR101558 A1 AR 101558A1
Authority
AR
Argentina
Prior art keywords
alkyl
substituted
group
co2h
haloalkyl
Prior art date
Application number
ARP150102622A
Other languages
English (en)
Inventor
He Yuanjun
Kamenecka Theodore
Original Assignee
Eolas Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eolas Therapeutics Inc filed Critical Eolas Therapeutics Inc
Publication of AR101558A1 publication Critical patent/AR101558A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto caracterizado porque es de fórmula (1), donde X es NR⁴ ó O; R¹ es un grupo heteroarilo monocíclico o bicíclico, donde R¹ no está sustituido o está sustituido con uno o más sustituyentes seleccionados en forma independiente entre el grupo que consiste en alquilo, haloalquilo, halo, -OH, -O-alquilo, -CN, -NRᵃRᵇ, -N(Rᵃ)C(O)alquilo, -N(Rᵃ)CO₂-alquilo, -N(Rᵃ)SO₂-alquilo, -C(O)alquilo, -CO₂H, -CO₂-alquilo, -CONRᵃRᵇ, -SO₂-alquilo, y -SO₂NRᵃRᵇ; donde Rᵃ y Rᵇ son en forma independiente entre sí H o alquilo; R² es fenilo o un heteroarilo monocíclico, donde R² no está sustituido o está sustituido con uno o más sustituyentes seleccionados en forma independiente entre el grupo que consiste en alquilo, haloalquilo, cicloalquilo, halo, -OH, -O-alquilo, -CN, -NRᶜRᵈ, -N(Rᵃ)C(O)alquilo, -N(Rᶜ)CO₂-alquilo, -N(Rᶜ)SO₂-alquilo, -C(O)alquilo, -CO₂H, -CO₂-alquilo, -CONRᶜRᵈ, -SO₂-alquilo, y -SO₂NRᶜRᵈ; donde Rᶜ y Rᵈ son en forma independiente entre sí H o alquilo; R³ es fenilo o un heteroarilo monocíclico, donde R³ no está sustituido o está sustituido con uno o más sustituyentes seleccionados en forma independiente entre el grupo que consiste en alquilo, haloalquilo, halo, -OH, -O-alquilo, -CN, -NRᵉRᶠ, -N(Rᵉ)C(O)alquilo, -N(Rᵉ)CO₂-alquilo, -N(Rᵉ)SO₂-alquilo, -C(O)alquilo, -CO₂H, -CO₂-alquilo, -CONRᵉRᶠ, -SO₂-alquilo, y -SO₂NRᵉRᶠ; donde Rᵉ y Rᶠ son en forma independiente entre sí H o alquilo; y R⁴ es H o alquilo; o una sal farmacéuticamente aceptable del mismo.
ARP150102622A 2014-08-13 2015-08-13 Difluoropirrolidinas como moduladores del receptor de orexina AR101558A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462037024P 2014-08-13 2014-08-13

Publications (1)

Publication Number Publication Date
AR101558A1 true AR101558A1 (es) 2016-12-28

Family

ID=55304607

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150102622A AR101558A1 (es) 2014-08-13 2015-08-13 Difluoropirrolidinas como moduladores del receptor de orexina

Country Status (8)

Country Link
US (1) US10221170B2 (es)
EP (1) EP3180332B1 (es)
JP (1) JP6663909B2 (es)
AR (1) AR101558A1 (es)
ES (1) ES2901418T3 (es)
TW (1) TW201613902A (es)
UY (1) UY36272A (es)
WO (1) WO2016025669A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2491038T3 (da) 2009-10-23 2016-07-18 Janssen Pharmaceutica Nv Disubstituerede octahydropyrrolo [3,4-c]pyrroler som orexin receptormodulatorer
HRP20220906T1 (hr) 2016-02-12 2022-10-14 Astrazeneca Ab Halo-supstituirani piperidini kao modulatori receptora oreksina
PL3426251T3 (pl) 2016-03-10 2022-07-18 Janssen Pharmaceutica Nv Sposoby leczenia depresji za pomocą antagonistów receptora typu 2 oreksyny
CN106278918B (zh) * 2016-08-12 2018-05-11 合肥久诺医药科技有限公司 一种溴芬酸钠杂质标准品2-氨基-3-(4-溴苯甲酰基)苯甲酸的合成方法
EP3594202B1 (en) * 2017-03-08 2021-08-11 Takeda Pharmaceutical Company Limited Substituted pyrrolidine compound and use thereof
WO2018164191A1 (ja) 2017-03-08 2018-09-13 武田薬品工業株式会社 置換ピロリジン化合物およびその用途
TWI790264B (zh) 2017-08-03 2023-01-21 日商武田藥品工業股份有限公司 雜環化合物及其用途
WO2019027003A1 (ja) * 2017-08-03 2019-02-07 武田薬品工業株式会社 複素環化合物およびその用途
CN111132975B (zh) * 2017-09-28 2023-05-23 勃林格殷格翰国际有限公司 N-(2,2-二氟乙基)-n-[(嘧啶基氨基)丙基]芳基甲酰胺
EP3816154A4 (en) 2018-06-29 2022-03-30 Takeda Pharmaceutical Company Limited HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
WO2020004537A1 (ja) 2018-06-29 2020-01-02 武田薬品工業株式会社 複素環化合物およびその用途
JP7408569B2 (ja) 2018-12-12 2024-01-05 武田薬品工業株式会社 複素環化合物
WO2020122092A1 (ja) 2018-12-12 2020-06-18 武田薬品工業株式会社 複素環化合物
TWI841671B (zh) 2019-01-24 2024-05-11 日商第一三共股份有限公司 具有取代基之脲化合物
TWI832962B (zh) 2019-01-31 2024-02-21 日商武田藥品工業股份有限公司 雜環化合物及其用途
US11371351B2 (en) 2020-01-17 2022-06-28 Raytheon Technologies Corporation Multi-disk bladed rotor assembly for rotational equipment
US11208892B2 (en) 2020-01-17 2021-12-28 Raytheon Technologies Corporation Rotor assembly with multiple rotor disks
US11339673B2 (en) 2020-01-17 2022-05-24 Raytheon Technologies Corporation Rotor assembly with internal vanes
US11286781B2 (en) 2020-01-17 2022-03-29 Raytheon Technologies Corporation Multi-disk bladed rotor assembly for rotational equipment
US11434771B2 (en) 2020-01-17 2022-09-06 Raytheon Technologies Corporation Rotor blade pair for rotational equipment
US11401814B2 (en) 2020-01-17 2022-08-02 Raytheon Technologies Corporation Rotor assembly with internal vanes

Family Cites Families (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US5049578A (en) 1990-03-09 1991-09-17 E. R. Squibb & Sons, Inc. 1-aroyl or 1-acyl-2-2pyrrolidinyl-3,5-dihydroxy alkanoic and alkenoic acids, salts, esters and lactones
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
CN1229110C (zh) 1997-07-29 2005-11-30 阿尔康实验室公司 含半乳甘露聚糖聚合物和硼酸盐的眼用组合物
CA2318920A1 (en) 1998-01-29 1999-08-05 James W. Young Pharmaceutical uses of optically pure (-)-bupropion
EP1075478B1 (en) 1998-05-08 2003-04-16 SmithKline Beecham plc Phenylurea and phenylthio urea derivatives
WO2000047576A1 (en) 1999-02-12 2000-08-17 Smithkline Beecham Plc Cinnamide derivatives as orexin-1 receptors antagonists
AU2910600A (en) 1999-02-12 2000-08-29 Smithkline Beecham Plc Phenyl urea and phenyl thiourea derivatives
WO2000047577A1 (en) 1999-02-12 2000-08-17 Smithkline Beecham Plc Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists
WO2000071508A2 (en) 1999-05-24 2000-11-30 Cor Therapeutics, Inc. INHIBITORS OF FACTOR Xa
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6838465B2 (en) 2000-05-11 2005-01-04 Banyu Pharmaceutical Co., Ltd. N-acyltetrahydroisoquinoline derivatives
US6677354B2 (en) 2000-06-16 2004-01-13 Smithkline Beecham P.L.C. Piperdines for use as orexin receptor antagonists
ATE286897T1 (de) 2000-11-28 2005-01-15 Smithkline Beecham Plc Morpholinderivate als antagonisten an orexinrezeptoren
WO2002051232A2 (en) 2000-12-27 2002-07-04 Actelion Pharmaceuticals Ltd. Novel benzazepines and related heterocyclic derivatives
WO2002089800A2 (en) 2001-05-05 2002-11-14 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
US7432270B2 (en) 2001-05-05 2008-10-07 Smithkline Beecham P.L.C. N-aroyl cyclic amines
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0126292D0 (en) 2001-11-01 2002-01-02 Smithkline Beecham Plc Compounds
GB0127145D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Compounds
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130341D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130335D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
MXPA04002269A (es) 2002-07-09 2004-06-29 Actelion Pharmaceuticals Ltd Derivados de 7,8,9,10-tetrahidro-6h-azepino,6,7,8,9-tetrahidro-pirido y 2,3-dihidro-2h-pirrolo[2,1-b]-quinazolinona.
ATE344261T1 (de) 2002-09-18 2006-11-15 Glaxo Group Ltd Cyclische n-aroylamine als orexinrezeptorantagonisten
CA2498091C (en) 2002-10-11 2011-03-22 Actelion Pharmaceuticals Ltd. Sulfonylamino-acetic acid derivatives
GB0225938D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225884D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225944D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
US6951882B2 (en) 2002-12-12 2005-10-04 Janssen Pharmaceutica N.V. Substituted 4-phenyl-[1,3]-dioxanes
RU2345985C2 (ru) 2003-03-26 2009-02-10 Актелион Фармасьютиклз Лтд. Производные тетрагидроизохинолилацетамида в качестве антагонистов орексинового рецептора
ATE383345T1 (de) 2003-04-28 2008-01-15 Actelion Pharmaceuticals Ltd Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US8512717B2 (en) 2003-08-07 2013-08-20 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using same
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
HUP0304101A3 (en) 2003-12-22 2008-10-28 Sanofi Aventis Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
HUP0400405A3 (en) 2004-02-10 2009-03-30 Sanofi Synthelabo Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
DK1751111T3 (en) 2004-03-01 2015-02-09 Actelion Pharmaceuticals Ltd SUBSTITUTED 1,2,3,4-tetrahydroisoquinoline derivatives
WO2006067224A2 (en) 2004-12-23 2006-06-29 Biovitrum Ab (Publ) Spiro-benzodioxole and spiro-benzodioxane compounds as orexin receptor antagonists
CA2603766A1 (en) 2005-04-12 2006-10-19 Merck & Co., Inc. Amidopropoxyphenyl orexin receptor antagonists
EP1885892A2 (en) 2005-05-03 2008-02-13 Ensemble Discovery Corporation Turnover probes and use thereof for nucleic acid detection
CA2609203A1 (en) 2005-05-23 2006-11-30 Merck & Co., Inc Proline bis-amide orexin receptor antagonists
EP1912655A2 (en) 2005-08-04 2008-04-23 Merck & Co., Inc. Aminoethane sulfonamide orexin receptor antagonists
US20090176789A1 (en) 2005-08-26 2009-07-09 Breslin Michael J Diazaspirodecane orexin receptor antagonists
AU2006316321A1 (en) 2005-11-22 2007-05-31 Merck & Co., Inc. Indole orexin receptor antagonists
CN101009515A (zh) 2006-01-24 2007-08-01 华为技术有限公司 通信终端设备管理方法及通信终端
TW200800020A (en) 2006-01-26 2008-01-01 Basf Ag Methods to use 3-pyridyl derivatives as pesticides
FR2896798A1 (fr) 2006-01-27 2007-08-03 Sanofi Aventis Sa Derives de sulfonamides, leur preparation et leur application en therapeutique
FR2896799B1 (fr) 2006-02-02 2008-03-28 Sanofi Aventis Sa Derives de sulfonamides, leur preparation et leur application en therapeutique
WO2007126934A2 (en) 2006-03-29 2007-11-08 Merck & Co., Inc. Amidoethylthioether orexin receptor antagonists
CA2646917A1 (en) 2006-04-11 2007-10-18 Actelion Pharmaceuticals Ltd Novel sulfonamide compounds
DE602007012072D1 (de) 2006-04-26 2011-03-03 Actelion Pharmaceuticals Ltd Orantagonisten
WO2007143813A1 (en) 2006-06-16 2007-12-21 Husky Injection Molding Systems Ltd. Preventative maintenance update system
JP2009543790A (ja) 2006-07-14 2009-12-10 メルク エンド カムパニー インコーポレーテッド ２−置換プロリンビス−アミドオレキシン受容体アンタゴニスト
AU2007272855B2 (en) 2006-07-14 2013-08-01 Merck Sharp & Dohme Corp. Substituted diazepan orexin receptor antagonists
EP2049110B1 (en) 2006-07-14 2014-08-20 Merck Sharp & Dohme Corp. Bridged diazepan orexin receptor antagonists
PL2069332T3 (pl) 2006-08-15 2011-07-29 Actelion Pharmaceuticals Ltd Związki azetydynowe jako antagoniści receptorów oreksynowych
US20100029617A1 (en) 2006-08-28 2010-02-04 Actelion Pharmaceuticals Ltd. 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulene derivatives as orexin receptor antagonists
EP2079690B1 (en) 2006-09-29 2010-09-15 Actelion Pharmaceuticals Ltd. 3-aza-bicyclo[3.1.0]hexane derivatives
ATE496043T1 (de) 2006-12-01 2011-02-15 Actelion Pharmaceuticals Ltd 3-heteroaryl (amino bzw. amido)-1- (biphenyl bzw. phenylthiazolyl) carbonylpiperdinderivate als orexinrezeptor-inhibitoren
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
US8188082B2 (en) 2006-12-22 2012-05-29 Actelion Pharmaceuticals Ltd. 5,6,7,8-tetrahydro-imidazo[1,5-α]pyrazine derivatives
CL2007003827A1 (es) 2006-12-28 2008-09-26 Actelion Pharmaceuticals Ltd Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras.
WO2008087611A2 (en) 2007-01-19 2008-07-24 Actelion Pharmaceuticals Ltd Pyrrolidine- and piperidine- bis-amide derivatives
CA2679817A1 (en) 2007-03-02 2008-09-12 Merck & Co., Inc. Bipyridine carboxamide orexin receptor antagonists
AU2008223916A1 (en) 2007-03-05 2008-09-12 F. Hoffmann-La Roche Ag Aminoamides as orexin antagonists
CN101636378A (zh) 2007-03-15 2010-01-27 弗·哈夫曼-拉罗切有限公司 作为食欲肽拮抗剂的丙二酰胺类
CL2008000836A1 (es) 2007-03-26 2008-11-07 Actelion Pharmaceuticals Ltd Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
CA2681163A1 (en) 2007-04-04 2008-10-16 F. Hoffmann-La Roche Ag Heterocycles as orexin antagonists
JP2010526869A (ja) 2007-05-14 2010-08-05 アクテリオン ファーマシューティカルズ リミテッド ２−シクロプロピル−チアゾール誘導体
WO2008143856A1 (en) 2007-05-18 2008-11-27 Merck & Co., Inc. Oxo bridged diazepan orexin receptor antagonists
US8030495B2 (en) 2007-05-23 2011-10-04 Coleman Paul J Cyclopropyl pyrrolidine orexin receptor antagonists
CA2687321C (en) 2007-05-23 2013-10-08 Merck & Co., Inc. Pyridyl piperidine orexin receptor antagonists
KR20100041805A (ko) 2007-07-03 2010-04-22 액테리온 파마슈티칼 리미티드 3-아자-비시클로[3.3.0]옥탄 화합물
JP2010534646A (ja) 2007-07-27 2010-11-11 アクテリオン ファーマシューティカルズ リミテッド トランス−３−アザ−ビシクロ［３．１．０］ヘキサン誘導体
RU2478099C2 (ru) 2007-07-27 2013-03-27 Актелион Фармасьютиклз Лтд Производные 2-аза-бицикло[3.3.0]октана
KR101171485B1 (ko) 2007-08-02 2012-08-07 에프. 호프만-라 로슈 아게 오렉신 수용체 길항제로서의 모노아마이드 유도체
US8003797B2 (en) 2007-08-09 2011-08-23 Merck Sharp & Dohme Corp. Pyridine carboxamide orexin receptor antagonists
CA2702292A1 (en) 2007-08-10 2009-02-19 Rudolf Mueller Bicyclic amides for ehancing glutamatergic synaptic responses
BRPI0815079A2 (pt) 2007-08-15 2015-02-03 Actelion Pharmaceuticals Ltd Composto dericado de 1,2-diamido-etileno, composição farmacêutica que contém e uso desse composto
JP2010540429A (ja) 2007-09-24 2010-12-24 アクテリオン ファーマシューティカルズ リミテッド オレキシン受容体拮抗薬としてのピロリジン類及びピペリジン類
AU2008319419A1 (en) 2007-10-29 2009-05-07 Merck Sharp & Dohme Corp. Substituted diazepan orexin receptor antagonists
WO2009079637A1 (en) 2007-12-18 2009-06-25 Concert Pharmaceuticals, Inc. Tetrahydroisoquinoline derivatives
WO2009080533A1 (en) 2007-12-21 2009-07-02 F. Hoffmann-La Roche Ag Heteroaryl derivatives as orexin receptor antagonists
CA2709050C (en) 2008-01-21 2016-06-14 F. Hoffmann-La Roche Ag Sulfonamides as orexin antagonists
KR101229603B1 (ko) 2008-02-12 2013-02-04 에프. 호프만-라 로슈 아게 피페리딘 설폰아미드 유도체
AU2009215243A1 (en) 2008-02-21 2009-08-27 Actelion Pharmaceuticals Ltd. 2-aza-bicyclo[2.2.1]heptane derivatives
GB0806536D0 (en) 2008-04-10 2008-05-14 Glaxo Group Ltd Novel compounds
CN102056920A (zh) 2008-06-11 2011-05-11 埃科特莱茵药品有限公司 用作食欲素受体拮抗剂的四唑化合物
EP2297102A1 (en) 2008-06-16 2011-03-23 F. Hoffmann-La Roche AG Heteroaromatic monoamides as orexinin receptor antagonists
CN102076694A (zh) 2008-06-25 2011-05-25 埃科特莱茵药品有限公司 5，6，7，8-四氢-咪唑并[1，5-a]吡嗪化合物
US20110105491A1 (en) 2008-07-07 2011-05-05 Hamed Aissaoui Thiazolidine compounds as orexin receptor antagonists
AU2009276091A1 (en) 2008-07-29 2010-02-04 F. Hoffmann-La Roche Ag Pyrrolidin-3-ylmethyl-amine as orexin antagonists
AR072899A1 (es) 2008-08-07 2010-09-29 Merck Sharp & Dohme Derivados de terpiridina-carboxamida antagonistas de receptores de orexina, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del insomnio y la obesidad.
EP2161266A1 (en) 2008-08-22 2010-03-10 EVOTEC Neurosciences GmbH Benzofuran derivatives as orexin receptor antagonists
WO2010038200A1 (en) 2008-10-01 2010-04-08 Actelion Pharmaceuticals Ltd Oxazolidine compounds as orexin receptor antagonists
CN102164896A (zh) 2008-10-14 2011-08-24 埃科特莱茵药品有限公司 苯乙基酰胺衍生物及其杂环类似物
CA2740190A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,3-disubstituted piperidine orexin receptor antagonists
EP2350066B1 (en) 2008-10-21 2013-08-28 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
JP2012506377A (ja) 2008-10-21 2012-03-15 メルク・シャープ・エンド・ドーム・コーポレイション ２，４−二置換フェニルカルボキサミド・オレキシン受容体アンタゴニスト
EP2349270B1 (en) 2008-10-21 2015-09-09 Merck Sharp & Dohme Corp. 2,5-disubstituted morpholine orexin receptor antagonists
JP2012506379A (ja) 2008-10-21 2012-03-15 メルク・シャープ・エンド・ドーム・コーポレイション 二置換アゼパンオレキシン受容体アンタゴニスト
AU2009307915A1 (en) 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
CN102272103B (zh) 2008-10-30 2015-10-21 默沙东公司 异烟酰胺食欲素受体拮抗剂
CA2741649A1 (en) 2008-10-30 2010-05-06 Merck Sharp & Dohme Corp. Pyridazine carboxamide orexin receptor antagonists
EP2349262B1 (en) 2008-10-30 2014-06-25 Merck Sharp & Dohme Corp. 2,5-disubstituted phenyl carboxamide orexin receptor antagonists
EP2358711A1 (en) 2008-11-26 2011-08-24 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
WO2010060472A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Imidazopyridazine derivatives acting as orexin antagonists
JP2012509911A (ja) 2008-11-26 2012-04-26 グラクソ グループ リミテッド 新規の化合物
TW201031407A (en) 2008-12-02 2010-09-01 Glaxo Group Ltd Novel compounds
UY32277A (es) 2008-12-02 2010-05-31 Glaxo Group Ltd Derivados de n-{[1r,4s,6r)-3-(2-piridinilcarbonil)-3-azabiciclo[4.1.0-il}metil}-2heteroarilamina y uso de los mismos
JP2010155827A (ja) 2008-12-04 2010-07-15 Takeda Chem Ind Ltd スピロ環化合物
GB0823467D0 (en) 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
US20100222396A1 (en) 2009-01-30 2010-09-02 Novartis Ag 4-aryl-butane-1,3-diamides
EA201171293A1 (ru) 2009-04-24 2012-05-30 Глэксо Груп Лимитед 3-азабицикло[4.1.0]гептаны, применяемые в качестве антагонистов орексина
EP2451281A4 (en) 2009-07-09 2013-03-13 Merck Sharp & Dohme TETRAHYDRONAPHTHYDRIN-orexin receptor Antagonist
EP2275421A1 (en) 2009-07-15 2011-01-19 Rottapharm S.p.A. Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction
WO2011016234A1 (en) 2009-08-04 2011-02-10 Raqualia Pharma Inc. Picolinamide derivatives as ttx-s blockers
JP2013502447A (ja) 2009-08-24 2013-01-24 グラクソ グループ リミテッド 睡眠障害の治療のためのオレキシン受容体アンタゴニストとしての５−メチル−ピペリジン誘導体
JP2013502448A (ja) 2009-08-24 2013-01-24 グラクソ グループ リミテッド オレキシンアンタゴニストとして用いられるピペリジン誘導体
DK2491038T3 (da) 2009-10-23 2016-07-18 Janssen Pharmaceutica Nv Disubstituerede octahydropyrrolo [3,4-c]pyrroler som orexin receptormodulatorer
US9062044B2 (en) 2009-10-23 2015-06-23 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
WO2011050200A1 (en) 2009-10-23 2011-04-28 Janssen Pharmaceutica Nv Fused heterocyclic compounds as orexin receptor modulators
EP2493299A4 (en) 2009-10-29 2013-04-17 Merck Sharp & Dohme TERTIARY AMIDOREXIN RECEPTOR ANTAGONISTS
EP2504316A1 (en) 2009-11-23 2012-10-03 MSD Oss B.V. Heterocylic compounds as antagonists of the orexin receptors
WO2011073316A1 (en) 2009-12-18 2011-06-23 Novartis Ag 4-aryl-butane-1,3-diamides
EP2516439B1 (en) 2009-12-21 2014-01-22 Novartis AG Diaza-spiro[5.5]undecanes as orexin receptor antagonists
US8742106B2 (en) 2009-12-21 2014-06-03 Novartis Ag Disubstituted heteroaryl-fused pyridines
WO2011138266A1 (en) 2010-05-03 2011-11-10 Evotec Ag Indolizine and imidazopyridine derivatives as orexin receptor antagonists
WO2011138265A2 (en) 2010-05-03 2011-11-10 Evotec Ag Indole and indazole derivatives as orexin receptor antagonists
SG191103A1 (en) 2010-12-17 2013-08-30 Taisho Pharmaceutical Co Ltd Pyrazole derivative
US20120165331A1 (en) 2010-12-22 2012-06-28 Sangamesh Badiger Di/tri-aza-spiro-C9-C11alkanes
WO2012085857A1 (en) 2010-12-22 2012-06-28 Actelion Pharmaceuticals Ltd 3,8-diaza-bicyclo[4.2.0]oct-3-yl amides
US20120165339A1 (en) 2010-12-22 2012-06-28 Eisai R&D Management Co., Ltd. Cyclopropane derivatives
WO2012089607A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors
WO2012089606A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
EP2675801B1 (en) 2011-02-18 2015-04-08 Actelion Pharmaceuticals Ltd. Novel pyrazole and imidazole derivatives useful as orexin antagonists
WO2012114252A1 (en) 2011-02-21 2012-08-30 Actelion Pharmaceuticals Ltd Novel indole and pyrrolopyridine amides
WO2012145581A1 (en) 2011-04-20 2012-10-26 Janssen Pharmaceutica Nv Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
US20140081025A1 (en) 2011-05-10 2014-03-20 Taisho Pharmaceutical Co., Ltd. Heteroaromatic ring derivative
WO2013005755A1 (ja) 2011-07-05 2013-01-10 大正製薬株式会社 メチルピペリジン誘導体
WO2013050938A1 (en) 2011-10-04 2013-04-11 Actelion Pharmaceuticals Ltd 3,7-diazabicyclo[3.3.1]nonane and 9-oxa-3,7-diazabicyclo[3.3.1]nonane derivatives
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
WO2013059163A1 (en) 2011-10-21 2013-04-25 Merck Sharp & Dohme Corp. 2,5-disubstituted thiomorpholine orexin receptor antagonists
WO2013062857A1 (en) 2011-10-25 2013-05-02 Merck Sharp & Dohme Corp. Piperidinyl alkyne orexin receptor antagonists
WO2013062858A1 (en) 2011-10-25 2013-05-02 Merck Sharp & Dohme Corp. Isoxazolopyridine orexin receptor antagonists
US9150566B2 (en) 2011-11-08 2015-10-06 Actelion Pharmaceuticals Ltd. 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-YL)picolinamide derivatives as orexin receptor antagonists
ITMI20112329A1 (it) 2011-12-21 2013-06-22 Rottapharm Spa Nuovi derivati spiro amminici
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
NZ628491A (en) 2012-02-07 2016-06-24 Eolas Therapeutics Inc Substituted prolines / piperidines as orexin receptor antagonists
BR112014019909B1 (pt) 2012-02-17 2020-01-28 Eisai R&D Man Co Ltd processo para produção de compostos úteis como antagonistas do receptor de orexina-2
ITMI20120322A1 (it) 2012-03-01 2013-09-02 Rottapharm Spa Composti di 4,4-difluoro piperidina
ITMI20120424A1 (it) 2012-03-19 2013-09-20 Rottapharm Spa Composti chimici
TW201613891A (en) 2014-02-12 2016-04-16 Eolas Therapeutics Inc Substituted prolines / piperidines as orexin receptor antagonists

Also Published As

Publication number Publication date
EP3180332A4 (en) 2018-01-24
TW201613902A (en) 2016-04-16
EP3180332B1 (en) 2021-10-27
EP3180332A1 (en) 2017-06-21
UY36272A (es) 2016-02-29
US20170226103A1 (en) 2017-08-10
WO2016025669A1 (en) 2016-02-18
ES2901418T3 (es) 2022-03-22
US10221170B2 (en) 2019-03-05
JP6663909B2 (ja) 2020-03-13
JP2017524005A (ja) 2017-08-24

Similar Documents

Publication Publication Date Title
AR101558A1 (es) Difluoropirrolidinas como moduladores del receptor de orexina
LT3814347T (lt) Naftiridinono junginiai naudotini kaip t ląstelių aktyvatoriai
PH12018501096A1 (en) Modulators of chemokine receptors
DOP2017000149A (es) Compuestos de triazolopirimidina y usos de los mismos
CR20150418A (es) Compuestos de tetrahidropirrolotiazina
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
EA201992183A3 (ru) Синтез полициклических карбамоилпиридоновых соединений
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
NZ726356A (en) Processes for preparing antiviral compounds
MX2015010837A (es) Compuestos de antranilamida, sus mezclas y el uso de los mismos como pesticidas.
AR103170A1 (es) Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desordenes inflamatorios y osteoartritis
EA201591634A1 (ru) Дигидропиридопиримидиновые соединения
PH12016501941A1 (en) Use of heterocyclic compounds for controlling nematodes
EA201791684A1 (ru) Селективные ингибиторы bace1
MX2015012629A (es) Compuestos de imidazo piridina.
UY35333A (es) Compuestos de azabencimidazol
TN2018000020A1 (en) Colony stimulating factor-1 receptor (csf-1r) inhibitors.
CR20170005A (es) Derivados de insoindolina
AR095097A1 (es) Compuestos de fenoxietoxi
MA39843A (fr) Pyridine-2-amides utiles comme agonistes de cb2
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
EA201591915A1 (ru) Соединения феноксиэтил дигидро-1h-изохинолина
AR104293A1 (es) Indazolonas como moduladores de la señalización de tnf
AR093128A1 (es) Inhibidores de la syk
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы

Legal Events

Date Code Title Description
FB Suspension of granting procedure